Lifecore Biomedical, Inc. Common Stock
LFCRLifecore Biomedical, Inc. is a biopharmaceutical company specializing in the development, manufacturing, and marketing of advanced biomaterials, including hyaluronic acid-based products used in medical and aesthetic applications. Founded in 1983, the company serves sectors such as ophthalmology, orthopedics, and aesthetics, providing products that support tissue repair and regeneration.
Company News
A proposed class action settlement of $3,750,000 has been reached on behalf of purchasers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020, and March 19, 2024. The settlement requires court approval at a hearing scheduled for July 28, 2026. Class members must submit claim forms by July 7, 2026, to be eligible for dis...
Lifecore Biomedical announced it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product. This is the company's third commercial site transfer since October 2025. The product is expected to generate commercial revenue within 24 months and contribute to Lifecore's targeted 2029 ...
Johnson Fistel, PLLP announced investigations into potential securities law violations by Green Dot Corporation, Lifecore Biomedical, and Horizon Technology Finance on behalf of affected investors. Green Dot's stock declined approximately 7% following the company's announcement of delayed financial results for Q4 and full year 2025.
Johnson Fistel, PLLP announced investigations into three companies on March 16, 2026. Lifecore Biomedical issued disappointing 2026 revenue guidance of $120-125 million versus $141.4 million in 2025, citing customer loss and product launch delays, resulting in an 18% stock decline. The firm is also investigating Horizon Technology Finance and G-I...
Lifecore Biomedical's compensation committee approved equity inducement grants on January 14, 2026, awarding 1,738 RSUs and 8,775 stock options to two newly hired employees. The RSUs vest after three years, while stock options vest monthly over three years with a seven-year exercise term.
